Q-omics provides the consensus-scored GOLM2 profile across patient tissues and cancer cell-line models. GOLM2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GOLM2 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, GOLM2 protein abundance shows 22,086 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where GOLM2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GOLM2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GOLM2 survival associations across molecular data types. GOLM2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GOLM2 RNA expression–survival associations across cancer types. High GOLM2 expression shows unfavorable associations in UVM and KIRP, but favorable associations in KIRC, SKCM, PRAD and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GOLM2 RNA expression.
This table summarizes GOLM2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GOLM2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GOLM2 shows lower tumor expression in THCA, LUSC and UCEC and higher tumor expression in KIRC, KIRP and CHOL. The KIRC box plot shows higher GOLM2 RNA expression in tumor versus normal tissue (log2 FC = +0.412, t-test p < 0.001).
This table shows molecular features associated with GOLM2 in patient tissues and cancer cell lines. In patient samples, GOLM2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GOLM2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
